Scientists test cancer drug safety for patients with liver problems
NCT ID NCT07422610
Summary
This early-stage study aims to understand how liver function affects the way the body processes an experimental cancer drug called pelabresib. It will enroll 24 adults with advanced cancer, comparing those with normal liver function to those with moderate or severe liver impairment. The main goal is to gather safety and dosing information to see if the drug behaves differently in people with liver problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES AND HEPATIC IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.